Leaders in Supply & Demand Side Intelligence

Forgot your login?

Enter the e-mail address you used when you registered an account with IIR Energy.

A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.


Biocon Bags Approval for CytoSorb Therapy in Critical COVID-19 Cases, an Industrial Info Market Brief

Free News Article
Attachment Included

India's biopharmaceutical major Biocon Limited said its subsidiary Biocon Biologics Limited has received approval from the Drugs Controller General of India (DCGI) for its extracorporeal blood purification (EBP) device, CytoSorb, which could help reduce pro-inflammatory cytokines levels in critical COVID-19 patients.

According to a Biocon media release, the license will be effective until the COVID-19 outbreak is controlled in the country and will be used as an emergency therapy to treat COVID-19 patients who are 18 or above and are being treated in the intensive care unit (ICU) with confirmed or imminent respiratory failure. Industrial Info is tracking 19 projects from Biocon and its subsidiaries worth $224.57 million. Click here for a list and see map below.

Details on this Article:
Industry Segment: Market Brief
Word Count: 121 Words
Attachment: Biocon
Listen to Today's News News Audio Library Sync News Podcasts

Login or Register now for instant access!
Related Articles


This article is free for all Registered Members.

Register Now! All Fields are Required...

Pricing Help?

Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361

All Members Receive the Following Free Resources:

  • North American Project & Gap Spending
  • North American Plant Analysis by Industry & Market Region
  • Market Maps & Stats - Capital & Maintenance Activity
  • Current & Historic Economic Indicators
  • 30/60/90 Day Weather Forecast